Road to RAD: Lebrikizumab for AD

In a recent interview with Dermatology Times, Jonathan Silverberg, MD, PhD, MPH, professor of dermatology at George Washington University School of Medicine and Health Sciences, discussed the results of the recent ADvocate 1 and 2 studies, which ultimately led to the approval of lebrikizumab for atopic dermatitis (AD).

“What they found [during the ADvocate 1 and 2 studies] was EASI75 responses and 4-point responses in itch, physicial significance achieved as early as week 2, and then EASI90 and IGA clear/almost clear statistical significance achieved by week 4," Silverberg said. “But the efficacy continues to improve beyond those time points, out to week 16. We see really solid efficacy across all of those endpoints, plus many others that were examined in the publication.”

Silverberg, a co-chair of the conference, will be presenting on a number of topics, including new and upcoming therapies, managing itch, and more. He will be joined by co-chair Raj Chovatiya, MD, PhD, MSCI; Dermatology Times Editor in Chief Christopher Bunick, MD, PhD; Mona Shahriari, MD; and even more experts in the field. With presentations on everything from dose flexibility to late breaking research, there is sure to be something for everyone at RAD 2025.

Want to hear more pearls and expert insights on AD? Join us at the annual Revolutionizing Atopic Dermatitis Conference this June in Nashville, TN. Use code DT40 for 40% off your RAD 2025 registration.

For more expert insights on the topic, check out our conference coverage page. To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.